On October 16, Novo Nordisk A/S announced it acquired ocedurenone from KBP Biosciences PTE., Ltd., a biotechnology company. According to Novo’s press release, the acquisition was valued at $1.3 billion.
ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist that is currently being examined in the phase 3 trial, CLARION-CKD, in patients with uncontrolled hypertension and advanced chronic kidney disease. ocedurenone has been investigated in nine clinical trials including the BLOCK-CKD Phase 2b trial.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Novo Nordisk employs more than 57,100 people in 80 countries and markets its products in about 170 countries.
KBP Biosciences is a research and development organization dedicated to providing innovative therapies for unmet medical needs.
This transaction is Novo Nordisk’s third acquisition of 2023. KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP.
According to data captured in the LevinPro HC database, this transaction represents the 87th Pharmaceuticals acquisition of 2023. This is a slight increase from the year before when 80 Pharmaceuticals transactions were reported between January 1, 2022, and October 16, 2022.
